VS Media Holdings Ltd (VSME): Preloaded…

Play Episode

6min

Proactive - Interviews for investors

Nostra Terra Oil and Gas completes fundraise as it advances Pine Mills workovers

Nostra Terra Oil and Gas Company PLC (AIM:NTOG, OTC:NTOGF) CEO Paul Welch talked with Proactive's Stephen Gunnion about the company’s latest developments, including its recently completed £500,000 fundraise. The funds will be used to complete the phase two workover program at Pine Mills, addressing well integrity issues and optimising oil production. Welch highlighted that the company is currently profitable at existing oil prices and remains focused on maximising the potential of Pine Mills before exploring new opportunities. He also discussed the ongoing technical evaluation of the Fouke three location with their partner, with further updates expected. Welch noted that the water flood program, which restarted in September, has exceeded expectations, leading to increased oil production. As a result, part of the funds raised will go towards upgrading two pumping units to support higher output. Looking ahead, Welch emphasised that Nostra Terra is focused on maintaining a solid, profitable base while evaluating further growth opportunities. He pointed out that the company has additional behind-pipe opportunities and untapped potential within Pine Mills, positioning it for continued success. For more updates on Nostra Terra Oil and Gas, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for more interviews and insights. #NostraTerra #OilAndGas #EnergyInvesting #OilProduction #Fundraising #Investing #StockMarket #EnergySector #OilIndustry #TexasOil

Proactive - Interviews for investors

Immunic presents at ACTRIMS forum as it awaits key CALLIPER MS trial data

Immunic Therapeutics chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company's strong presence at the 10th annual ACTRIMS Forum, where it presented two key posters on multiple sclerosis (MS). He highlighted that Immunic’s investigational drug, vidofludimus calcium, has potential neuroprotective properties that may benefit both relapsing and progressive MS patients. One of the posters examined baseline characteristics of past progressive MS trials and contrasted them with Immunic’s CALLIPER trial, designed for non-relapsing patients with minimal inflammatory activity. The second poster explored preclinical data on the drug’s mechanism of action, emphasizing its potential to target activated microglia and support neuron survival. Muehler noted significant engagement from the MS community at ACTRIMS, with many keenly anticipating the CALLIPER trial’s readout in April. “It’s really one of the very few late-stage drugs with a potential neuroprotective effect,” he said, adding that the data could provide new hope for progressive MS patients who currently have limited treatment options. Stay tuned for more updates on Immunic’s progress. For more interviews, subscribe to Proactive’s YouTube channel, like this video, and turn on notifications! #ImmunicTherapeutics #MSResearch #Neuroprotection #CALLIPERTrial #MultipleSclerosis #Biotech #DrugDevelopment #ClinicalTrials #MedicalBreakthrough #ACTRIMS

Proactive - Interviews for investors

Bitwise’s Bradley Duke on the BTCG ETP: gold & Bitcoin combined

Bitwise Asset Management European head Bradley Duke talked with Proactive about Bitcoin’s recent price movements and the company’s latest product launch. Duke discussed the volatility of Bitcoin, noting both its tailwinds—such as increased demand from corporate investors and national reserves—and the headwinds, including geopolitical uncertainties. He pointed out that institutional investors are turning instead to alternative safe-haven assets like gold. The conversation then shifted to Bitwise’s latest product, Bitwise Diaman Bitcoin & Gold ETP (BTCG), which launched today on Euronext in Paris and Amsterdam. Duke explained that the product is a collaboration with Diaman Partners, part of asset manager Azimut. The ETP dynamically allocates between Bitcoin and gold based on an index that considers drawdowns and recovery rates. "We’ve looked at the performance of this index versus the S&P 500, Nasdaq 100, and gold alone, and it has outperformed considerably," said Duke. He emphasised that while past performance is no guarantee of future results, the product arrives at a time when institutions are actively seeking alternative safe-haven assets. For more insights and interviews, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and enable notifications for updates. #Bitcoin #Gold #BTCG #Bitwise #CryptoInvesting #DigitalAssets #SafeHaven #ETP #Investment #Markets

Proactive - Interviews for investors

Clinical study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE

Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to share updates on the ongoing SKNJCT-003 clinical study, which is being conducted at nine sites across the United States and aims to randomize 60 patients. An interim analysis conducted after enrolling more than half of the targeted participants has shown encouraging results. The study reports a clinical clearance rate exceeding 60%, with the investigational therapy demonstrating strong tolerability across both tested dosage levels. Notably, no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) have been observed, and there have been no systemic effects or clinically significant abnormalities in laboratory results, ECGs, vital signs, or physical exams. These promising findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. In parallel, the company is advancing its clinical initiatives for non-invasive basal cell carcinoma treatment with a newly proposed study. This randomized, double-blind, placebo-controlled, multi-center trial has been submitted for approval to the UAE Department of Health. The study aims to enroll up to 36 patients at prominent medical institutions, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and the American Hospital of Dubai. Participants will be assigned in a 1:1:1 ratio to receive either a placebo or one of two dosage levels of the experimental treatment. This expansion into the UAE represents a significant step forward in the company’s mission to develop innovative, non-invasive therapies for skin cancer, broadening its global clinical footprint and reinforcing its commitment to advancing patient care. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Followers	112
Posts	17594
Boards Moderated	0
Alias Born	06/24/2014

Volume:	65
Day Range:
Bid:	0.894
Ask:	0.925
Last Trade Time:	7:25:27 AM EDT
Total Trades:	2

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

VSME Detailed Quote

Recent VSME News

More VSME News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent VSME News

Go Ad-Free